NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing central nervous system treatments through its wholly owned operating subsidiary, NeuroRx, and providing interventional psychiatric care through HOPE Therapeutics, which it founded and majority owns. Its drug candidates… From the company’s description.
In fiscal 2025, NRX Pharmaceuticals, Inc. reported revenue of $1.23M and a net loss of $28.62M. Operations used $14.11M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NRX Pharmaceuticals, Inc. does
In the company’s own words
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing central nervous system treatments through its wholly owned operating subsidiary, NeuroRx, and providing interventional psychiatric care through HOPE Therapeutics, which it founded and majority owns. Its drug candidates target neuroplasticity by modulating NMDA receptors and include KETAFREE™, a preservative-free generic ketamine formulation; NRX-100, preservative-free intravenous ketamine being developed for depression with suicidal ideation; and NRX-101, an oral combination of D-cycloserine and lurasidone being developed for bipolar depression and as a potential TMS adjunct. HOPE clinics provide treatment for patients with treatment-resistant depression and PTSD using TMS, ketamine and other neuroplastic drugs, digital therapeutics, hyperbaric therapy, psychotherapy and medication management. The company reports its drug development and medical services activities; HOPE recorded its first clinical revenue in 2025 and operated five Florida locations. NRx had approximately 29 full-time employees as of December 31, 2025. Its website is https://www.nrxpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 1719406
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NRX Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NRX Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NRX Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NRX Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NRX Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”